Edition:
United States

Roche Holding AG (RHHBY.PK)

RHHBY.PK on OTC Markets Group

32.24USD
4:00pm EDT
Change (% chg)

$0.10 (+0.33%)
Prev Close
$32.14
Open
$32.31
Day's High
$32.45
Day's Low
$32.24
Volume
847,814
Avg. Vol
1,349,717
52-wk High
$33.77
52-wk Low
$25.25

Latest Key Developments (Source: Significant Developments)

Genentech says FDA advisory committee unanimously recommends approval of co’s subcutaneous rituximab for certain blood cancers
Wednesday, 29 Mar 2017 12:09pm EDT 

Genentech: FDA advisory committee unanimously recommends approval of Genentech's subcutaneous rituximab for certain blood cancers .FDA is expected to make a decision on approval for rituximab by June 26, 2017.  Full Article

FDA approves Genentech's MS drug Ocrevus
Tuesday, 28 Mar 2017 09:06pm EDT 

Roche Holding Ag : FDA approves Genentech's Ocrevus (ocrelizumab) for relapsing and primary progressive forms of multiple sclerosis .Ocrevus will be available to people in U.S. within two weeks.  Full Article

Genentech says FDA grants breakthrough therapy designation for Rituximab in Pemphigus Vulgaris
Friday, 24 Mar 2017 01:00am EDT 

Genentech: FDA grants breakthrough therapy designation for Rituxan (rituximab) in Pemphigus Vulgaris .U.S. Food and drug administration (fda) has granted breakthrough therapy designation status to Rituxan.  Full Article

Chugai Pharmaceutical to issue 123,000 shares for 469.9 mln yen
Thursday, 23 Mar 2017 04:05am EDT 

Chugai Pharmaceutical Co Ltd <4519.T>:Says it plans to issue 123,000 shares for 469.9 million yen in total.  Full Article

Roche Diagnostics Canada says Health Canada has approved cobas EGFR mutation test v2
Tuesday, 14 Mar 2017 09:49am EDT 

Roche Diagnostics Canada - :Health Canada has approved cobas EGFR mutation test v2.  Full Article

Mylan reports global settlement, license agreements with Genentech, Roche
Monday, 13 Mar 2017 08:00am EDT 

Mylan NV : Mylan announces global settlement and license agreements with Genentech and Roche on herceptin . Mylan NV- all other terms and conditions of settlement and license agreement are confidential . Mylan NV- has agreed to withdraw its pending inter partes review challenges against two U.S. Genentech patents as part of settlement . Mylan NV- licenses pertain to all countries except Japan, Brazil and Mexico . Mylan NV- settlement also eliminates further patent litigation expenses associated with Genentech and Roche .Mylan NV- has agreed to terms of a global settlement with Genentech, Inc. And F. Hoffmann-La Roche Ltd. in relation to patents for herceptin.  Full Article

Exelixis announces clinical trial collaboration with Roche
Monday, 27 Feb 2017 06:59am EST 

Exelixis Inc : Exelixis announces clinical trial collaboration with Roche to evaluate cabozantinib and atezolizumab in locally advanced or metastatic solid tumors . Exelixis Inc - expect to begin patient enrollment mid-year 2017 .Exelixis - study will evaluate potential of this combination in multiple solid tumors, including advanced renal cell carcinoma, urothelial carcinoma.  Full Article

Roche says Alecensa approved in EU for lung cancer
Tuesday, 21 Feb 2017 01:00am EST 

Roche Holding Ag : Says receives eu approval of alecensa (alectinib) for people with previously treated alk-positive non-small cell lung cancer Further company coverage: [ROG.S] (Reporting By Zurich newsroom) ((zurich.newsroom@thomsonreuters.com; +41 58 306 7336;)).  Full Article

Roche Holding reports 8.5pct passive stake in Senseonics Holdings as of Dec 31 - SEC Filing
Tuesday, 7 Feb 2017 04:50pm EST 

Senseonics Holdings Inc :Roche Holding Ltd reports 8.5% passive stake in Senseonics Holdings Inc as of December 31, 2016 - SEC Filing.  Full Article

Roche Canada says Health Canada approves Gazyva
Tuesday, 7 Feb 2017 07:30am EST 

Roche Holding AG - :Roche Canada - Health Canada approves Gazyva for patients with previously treated follicular lymphoma.  Full Article

More From Around the Web

Photo

U.S. approves Roche drug that targets severe form of MS

ZURICH Roche's multiple sclerosis (MS) drug Ocrevus won U.S. approval, putting the potential blockbuster back on track after a brief delay and giving a lift to patients with a form of the disease that until now had no approved treatment.